Abstract
A quality management program was designed to eliminate false positive serological testing after administration of intravenous gamma globulin (IVIgG). The intervention and follow‐up chart review was performed in a tertiary care teaching hospital. After the index false positive test was reported, a multidisciplinary team sent memos to all affiliated physicians and devised a warning label to use in the patient charts after IVIgG administration. After the intervention, follow‐up of 28 patients who received a total of 162 doses of IVIgG revealed that five had at least one serologic test ordered which might have produced a false positive. However, chart review suggested that these serologic results did not influence patient treatment. Serological testing after IVIgG administration can generate erroneous results that can lead to costly delays in diagnosis and treatment. Process control actions can proactively foster proper laboratory ordering practices and interpretation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
